Search the Newsreel

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Neuronetics, Inc. announced an inducement grant of restricted stock units (RSUs) to its new Chief Financial Officer, Matthew Bennett. This grant, totaling 167,490 RSUs, was made outside of the company's existing equity compensation plans but was approved by the Compensation Committee in accordance with …

Neurocrine Biosciences, Inc. Revenue Breakdown – NASDAQ:NBIX

Neurocrine Biosciences, Inc. (BX:NB3) reported a total revenue of 2.27 billion CHF last year, primarily driven by its Pharmaceuticals segment. The majority of this revenue, also 2.27 billion CHF, came from operations within the United States. This indicates a strong reliance on the pharmaceutical …

Neuropace Inc (NPCE) Financial Health: Profitability & Balance Sheet Analysis

Neuropace Inc (NPCE) currently holds a financial score of 6.68, ranking 138 out of 200 in the Healthcare Equipment & Supplies industry, indicating a weak financial status and average operating efficiency. The company's latest quarterly revenue decreased by 2.02% year-over-year to $22.07M, with net …

Levi & Korsinsky Notifies Shareholders of Neumora Therapeutics, I

Levi & Korsinsky LLP has announced a class action lawsuit against Neumora Therapeutics, Inc. (NMRA) on behalf of shareholders who suffered losses. The lawsuit alleges that Neumora made false statements and concealed information regarding its Phase Three Program and Phase Two trial data for …

NeuroSense Therapeutics (NRSN) seeks reverse split amid Nasdaq compliance push

NeuroSense Therapeutics (NRSN) is calling a Special Meeting of Shareholders on August 26, 2026, to seek approval for a reverse stock split. This move is aimed at regaining compliance with Nasdaq's minimum bid price ($1.00) and market value of listed securities ($35 million) requirements, …

NeuroSense Therapeutics (NRSN) revises Capital on Demand share sales deal

NeuroSense Therapeutics has amended its Capital on Demand Sales Agreement with JonesTrading Institutional Services LLC, updating the referenced registration statement to a new Form F-3 (File No. 333-293060), which became effective on July 31, 2026. Under the revised agreement, the company can offer and …

NEUP|Neuphoria Therapeutics Inc|Price:3.880|Chg%:-0.040

This article provides a comprehensive stock analysis of Neuphoria Therapeutics Inc (NEUP) from TradingKey. It highlights the company's strong fundamentals and high growth potential, despite its stock trading sideways between support and resistance levels. The analysis also covers its valuation, institutional ownership, analyst ratings, …

Neuberger fund's $0.12 payout may include return of capital

Neuberger Next Generation Connectivity Fund (NBXG) has declared a monthly distribution of $0.12 per share, payable on August 31, 2026, to shareholders of record on August 17, 2026. While the fund aims for stable monthly payouts, these distributions may include net investment income, capital …

Neurocrine Biosciences (NBIX) Is Down 5.2% After Earnings Beat And Raised INGREZZA Outlook Has The Bull Case Changed?

Neurocrine Biosciences reported strong Q2 2026 earnings with revenue of US$959.0 million and net income of US$144.4 million, and raised its INGREZZA sales guidance. Despite these positive results, the stock fell 5.2%, reflecting ongoing concerns about pricing pressure and product concentration risks within its …

Neurocrine Biosciences Q2 Earnings Call Highlights

Neurocrine Biosciences reported strong Q2 2026 revenues exceeding $950 million, a nearly 40% year-over-year increase, driven by INGREZZA and CRENESSITY sales, plus VYKAT XR's partial contribution. The company raised its full-year INGREZZA sales guidance and is integrating VYKAT XR following a $2.9 billion acquisition. …

Neurocrine Biosciences Inc (NBIX) Shares Fall 10.1% -- What GF S

Neurocrine Biosciences Inc (NBIX) shares dropped 10.1% to $166.80, yet GuruFocus estimates the stock is undervalued with a GF Value™ of $192.59. The company holds a strong GF Score™ of 94/100, driven by excellent growth potential, but faces caution due to significant insider selling …

Price to book forward of Neuropace, Inc. – NASDAQ:NPCE

This page provides financial information for Neuropace, Inc. (NASDAQ: NPCE), specifically focusing on its price to book forward ratio. It includes links to various financial data, news, and community sections related to the company on the TradingView platform.

Neurocrine Biosciences (NBIX) quantifies Soleno acquisition and VYKAT XR impact

Aspen's Parkinson's Cell Therapy Gets FDA RMAT Designation—Not Approval

ClearPoint Neuro announced that its partner Aspen Neuroscience received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for sasineprocel, an investigational Parkinson's disease therapy. This designation expedites development and review but does not constitute FDA approval. ClearPoint Neuro's Navigation System and SmartFlow Cannula are utilized …

Trading the Move, Not the Narrative: (NPCE) Edition

This article provides an AI-driven analysis of Neuropace Inc. (NPCE), highlighting weak near and mid-term sentiment despite a positive long-term outlook. It presents three institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones. The analysis emphasizes elevated downside risk …

(NEU) Volatility Zones as Tactical Triggers

This article analyzes Newmarket Corp (NEU) using AI models, identifying strong near and mid-term sentiment, and potential for long-term growth. It provides three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones. The analysis also includes multi-timeframe signal …

(NBXG) Price Dynamics and Execution-Aware Positioning

This article analyzes the price dynamics and execution-aware positioning for Neuberger Berman Next Generation Connectivity Fund Inc. (NASDAQ: NBXG). It highlights weak near and mid-term sentiment potentially challenging a long-term positive outlook, identifies a mid-channel oscillation pattern, and outlines distinct trading strategies with risk …

Neuropace, Inc. Revenue Breakdown – NASDAQ:NPCE

Neuropace, Inc. (NASDAQ: NPCE) generated $99.99 million in revenue last year, primarily from its Medical Device segment, which contributed the entire amount. This marks an increase from $79.91 million in the previous year. The United States was the company's largest market, accounting for all …

ClearPoint Neuro Congratulates Partner Aspen Neuroscience on FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Sasineprocel

ClearPoint Neuro congratulates its partner Aspen Neuroscience on receiving the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation for sasineprocel (ANPD001), an investigational autologous cell replacement therapy for Parkinson's disease. This designation will support an expedited development and review pathway for Aspen's therapy, which utilizes …

Neurocrine Biosciences Slides as Q2 Results and Outlook Leave Little Room for Upside

Neurocrine Biosciences (NBIX) stock fell 10.0% following its Q2 2026 earnings release, which investors viewed as mixed rather than exceeding expectations. Despite solid demand for key products like INGREZZA, the company largely reaffirmed its existing outlook instead of raising guidance, leading to investor disappointment. …

Scancell merges with Nasdaq shell Neuphoria to fund USD 89m Phase III melanoma trial

UK-based Scancell Holdings plc has announced an all-share merger agreement with Neuphoria Therapeutics Inc., a move that will provide Scancell with a Nasdaq listing and up to $89 million in financing. This funding is earmarked for the registrational Phase III development of Scancell's melanoma …

Neurocrine Biosciences, Inc. Stock 12‑Month Price Target Raised to $209.63, Implies 13% Upside

Neurocrine Biosciences, Inc. (NBIX) has seen its average 12-month stock price target increased from $201.2 to $209.34 by 28 analysts, implying a potential 13% upside based on the July 30 closing price. The consensus rating among 31 covering analysts remains a "Buy," with 27 …

NBIX Q2 Earnings Call Highlights: Portfolio Expansion Drives Growth

Neurocrine Biosciences, Inc. NBIX highlighted the continued expansion of its commercial portfolio during its second-quarter 2026 earnings call, with management emphasizing growth from INGREZZA, CRENESSITY and the newly acquired VYKAT XR. The company also outlined upcoming clinical catalysts and its strategy to diversify beyond …

NewMarket (NEU) Reports Stronger First Half Results, Is The Valuation Still Compelling?

Guggenheim raises Neurocrine Bio stock price target on Ingrezza beat

Guggenheim has increased its price target for Neurocrine Biosciences Inc. (NASDAQ:NBIX) shares to $222 from $200, maintaining a Buy rating after the company's strong second-quarter results. The company reported Ingrezza sales significantly above consensus and raised its full-year 2026 Ingrezza sales guidance, driven by …

NewMarket Corp (NEU) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of NewMarket Corp (NEU), detailing its current price momentum, support and resistance levels, and various technical indicators like MACD, RSI, and Moving Averages. It highlights that NEU's price momentum score is 4.27, suggesting suitability for range-bound swing trading …

[10-Q] NEUROCRINE BIOSCIENCES INC Quarterly Earnings Report

Neurocrine Biosciences Inc. (NBIX) filed its quarterly earnings report (Form 10-Q) with the SEC, detailing its financial performance for the quarter ended June 30, 2026. Key highlights include the completion of the Soleno Therapeutics Inc. acquisition, adding VYKAT XR to its commercial portfolio, and …

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Consensus Rating of "Moderate Buy" from Brokerages

Neumora Therapeutics, Inc. (NASDAQ:NMRA) has received a "Moderate Buy" consensus rating from ten brokerages, with an average 12-month price target of $6.57 against a current price of $1.65. While several analysts recently lowered their price targets, the general sentiment remains positive. Institutional investors hold …

Neuropace Inc (NPCE) Institutional Confidence

Neuropace Inc (NPCE) has an institutional shareholding score of 10.00, ranking 1st out of 199 in its industry. The institutional shareholding proportion is 99.26%, showing a 7.21% quarter-over-quarter increase. James Simons is the largest institutional shareholder, holding 0.51% of outstanding shares.

AIFF Q3 1998 Earnings: Pre-Revenue Neurotech Firm Posts Deep Loss While Shares Advance - Earnings Weakness Phase

Alto Neuroscience (ANRO) Slips 5.45% to $27.07 as Clinical-Stage Biotech Faces Profit-Taking Pressure - Sign of Weakness

AIFF Q3 1998 Earnings: $12.90 Per-Share Loss Misses +$3.37 Estimate, Yet Shares Rally 5.94% - Downward Estimate Revision

AIFF Q3 1998 Earnings: Net Loss of $12.90 Per Share Versus $3.37 Estimate; Shares Climb 5.94% - Pre-Earnings Setup

Contineum Therapeutics (NASDAQ:CTNM) Trading Down 9.1% - Should You Sell?

Could Neurotech (ASX:NTI) Lead a Sharper Sector Read?

Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results

Total Second-Quarter 2026 Revenue Grew 39% Year-Over-Year to $959 Million INGREZZA® (valbenazine) 2026 Net Sales Guidance Raised to $2.825 to $2.875 Billion Acquisition of Soleno Therapeutics Completed in May 2026 SAN DIEGO, July 30, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced …